Up­dat­ed: Leena Gand­hi leaves Dana-Far­ber for check­point in­hibitor biotech

Im­muno-on­col­o­gy pi­o­neer Leena Gand­hi is on the move once again.

Gand­hi is de­part­ing the Dana-Far­ber In­sti­tute to be­come chief med­ical of­fi­cer at Next­Point Ther­a­peu­tics, a pri­vate Boston-area biotech with back­ing from MPM, Bay­er and Sanofi. Tues­day’s an­nounce­ment comes about a month and a half af­ter Next­Point closed an $80 mil­lion Se­ries B.

In an in­ter­view Tues­day af­ter­noon, Gand­hi told End­points News she start­ed the job about a month ago and that the sci­ence Next­Point is work­ing on rep­re­sents one of I/O’s next chal­lenges.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER